Pluri (NASDAQ:PLUR) Shares Set to Reverse Split on Monday, April 1st

Pluri Inc. (NASDAQ:PLUR) shares are scheduled to reverse split on Monday, April 1st. The 1-8 reverse split was announced on Monday, April 1st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 1st.

Pluri Trading Down 8.4 %

PLUR opened at $0.81 on Friday. The company has a fifty day moving average price of $0.82 and a two-hundred day moving average price of $0.65. Pluri has a 1-year low of $0.43 and a 1-year high of $1.07. The company has a market cap of $33.43 million, a P/E ratio of -1.39 and a beta of 1.45. The company has a current ratio of 7.12, a quick ratio of 7.12 and a debt-to-equity ratio of 3.69.

Pluri (NASDAQ:PLUR) last issued its earnings results on Monday, February 12th. The company reported ($0.12) EPS for the quarter. Pluri had a negative net margin of 6,708.40% and a negative return on equity of 177.94%. The firm had revenue of $0.11 million during the quarter.

Institutional Trading of Pluri

Several hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. lifted its stake in shares of Pluri by 168.4% in the third quarter. Values First Advisors Inc. now owns 135,547 shares of the company’s stock valued at $81,000 after buying an additional 85,037 shares in the last quarter. Renaissance Technologies LLC acquired a new position in Pluri during the 3rd quarter valued at about $81,000. Jane Street Group LLC increased its holdings in Pluri by 166.5% during the 4th quarter. Jane Street Group LLC now owns 95,906 shares of the company’s stock worth $90,000 after purchasing an additional 59,920 shares in the last quarter. Finally, Citadel Advisors LLC raised its stake in shares of Pluri by 128.1% in the fourth quarter. Citadel Advisors LLC now owns 57,481 shares of the company’s stock worth $33,000 after purchasing an additional 32,279 shares during the last quarter. Institutional investors and hedge funds own 16.59% of the company’s stock.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.